These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29127931)

  • 61. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J; Llewellyn A; Soares M; Simmonds M; Wright K; Eastwood A; Palmer S
    Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
    Florea I; Loft H; Danchenko N; Rive B; Brignone M; Merikle E; Jacobsen PL; Sheehan DV
    Brain Behav; 2017 Mar; 7(3):e00622. PubMed ID: 28293465
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M; Bose R; Schmidt SN
    Curr Med Res Opin; 2024 Sep; 40(9):1637-1645. PubMed ID: 39110846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
    Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
    J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vilazodone: a review in major depressive disorder in adults.
    McCormack PL
    Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
    Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
    Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
    Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
    J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
    [No Abstract]   [Full Text] [Related]  

  • 69. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
    Montgomery SA; Gommoll CP; Chen C; Greenberg WM
    CNS Spectr; 2015 Apr; 20(2):148-56. PubMed ID: 24902007
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI; Tourkodimitris S; Ruth A
    J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vortioxetine: a review of its use in major depressive disorder.
    Garnock-Jones KP
    CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacotherapy of major depression in late life: what is the role of new agents?
    Patel K; Abdool PS; Rajji TK; Mulsant BH
    Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
    Zhang J; Mathis MV; Sellers JW; Kordzakhia G; Jackson AJ; Dow A; Yang P; Fossom L; Zhu H; Patel H; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Jan; 76(1):8-14. PubMed ID: 25562777
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
    Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
    J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
    Mattingly GW; Necking O; Schmidt SN; Reines E; Ren H
    Curr Med Res Opin; 2023 Apr; 39(4):613-619. PubMed ID: 36884024
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J; Wang Z; Li E
    Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vortioxetine overdose in a suicidal attempt: A case report.
    Mazza MG; Rossetti A; Botti ER; Clerici M
    Medicine (Baltimore); 2018 Jun; 97(25):e10788. PubMed ID: 29923970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.